Name (Synonyms) | Correlation |
---|
Name (Synonyms) | Correlation | |
---|---|---|
D001172 | Arthritis, Rheumatoid NIH | 0.38 |
D001168 | Arthritis NIH | 0.29 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0001370 | Rheumatoid arthritis HPO | 0.38 |
HP:0001369 | Arthritis HPO | 0.29 |
There is one clinical trial.
This Phase 1 single-dose, dose-escalation study is an open label trial evaluating the safety of CPI-006, a humanized monoclonal antibody targeting the CD73 cell-surface ectonucleotidase, as immunotherapy for stable hospitalized mild or moderately symptomatic COVID-19 patients.
Description: Incidence of adverse events (including serious adverse events and dose limiting toxicities).
Measure: Incidence of Treatment-Emergent Adverse Events to Determine Single Dose of CPI-006 That is Safe in Patients with COVID-19 Time: Up to 30 days after dose of CPI-006.Description: Measure changes in serum or plasma immunoglobulin anti-SARS CoV-2 levels.
Measure: Immunoglobulin Anti-SARS CoV-2 Levels Time: Baseline and Day 28.Description: Time to two consecutive negative nasal swab PCR SARS CoV-2 viral tests.
Measure: Negative Nasal Swab Polymerase Chain Reaction (PCR) SARS CoV-2 Viral Tests Time: Baseline to two consecutive negative nasal swab PCR SARS CoV-2 viral tests (separated by at least 48 hours).Description: Duration of COVID-19 related symptoms.
Measure: Duration of symptoms Time: Up to 24 weeks after dose of CPI-006.Description: Time to discharge from hospital.
Measure: Time to discharge Time: Up to 24 weeks after dose of CPI-006.Description: Rate of medical procedures during hospitalization.
Measure: Rate of medical procedures Time: Up to 24 weeks after dose of CPI-006.